Search
Sign In Register
Sign In Register
Home / The Science / iStopMM / Partnering with Binding Site

Partnering with Binding Site

    

iStopMM partnered with Binding Site to perform the screening tests in this study.

Samples were aliquoted and sent to the Binding Site laboratory in Birmingham, UK. There, they were screened for monoclonal protein by capillary zone electrophoresis and assayed for Free Light Chains, using Freelite® assays on the Optilite® analyser. Samples were also tested for immunoglobulin concentration (IgG, IgA, and IgM), and total protein5.

The Binding Site are partners of choice in this pivotal study because:

  • Of the combination of greater than 20 years of scientific expertise, with the shared commitment to improving patient lives through education, collaboration and innovation.
  • Freelite assays are supported by a wealth of scientific evidence with regards to the myeloma literature and are therefore considered as the gold standard in free light chain testing.
  • Freelite assays transformed clinical practice for the diagnosis and prognosis of monoclonal gammopathies, leading to their inclusion in the IMWG guidelines.
  • Binding Site demonstrated the capability to perform the testing in-house, with their highly skilled personnel and state of the art laboratories.

                                           Want to find out more?

Enter your details to receive the latest updates on the iStopMM Study
Sign up

Watch the webinar

Videos

Introducing the iStopMM trial

148,704 individuals were invited to be screened, with the…

Watch the webinar

Videos

An interview with Charles de Rohan

Charles de Rohan speaks about the Binding Site's role in the…

Watch the webinar

Literature

Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies

Sæmundur Rögnvaldsson et al

Discover more about Monoclonal Gammopathy of Undetermined Significance (MGUS)

What is MGUS? MGUS monitoring
References
    <ol> <li>Kyle, R. A. et al. <span style="color: #222222;">Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. <em>Leukemia</em> 24, 1121&ndash;1127 (2010).</span></li> <li>Sigurdardottir, E. E. et al. <span style="color: #222222; background: white;">The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma.&nbsp;<em>JAMA Oncol.</em>&nbsp;1, 168&ndash;174 (2015).</span></li> <li>Go, R. S., Gundrum, J. D. &amp; Neuner, J. M. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-medicare population analysis.&nbsp;<em style="color: #222222;">Clin. Lymphoma Myeloma Leuk.</em><span style="background-color: white; color: #222222;">&nbsp;15, 117&ndash;186 (2015).</span></li> <li>Goyal, G. et al. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.&nbsp;<em style="color: #222222;">Leukemia</em><span style="background-color: white; color: #222222;">&nbsp;33, 1273&ndash;1277 (2019).</span></li> <li>R&ouml;gnvaldsson, S., Love, T.J., Thorsteinsdottir, S.&nbsp;<em style="color: #222222;">et al.</em><span style="background-color: white; color: #222222;">&nbsp;Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.&nbsp;</span><em style="color: #222222;">Blood Cancer J.</em><span style="background-color: white; color: #222222;">&nbsp;11</span><strong style="color: #222222;">,&nbsp;</strong><span style="background-color: white; color: #222222;">94 (2021).</span></li> </ol>